INmune Bio Advances Key Patent for CORDStrom™ Platform in U.S.
Event summary
- INmune Bio has advanced its CORDStrom™ platform patent application to the U.S. national phase before the USPTO.
- The application received a favorable PCT Written Opinion, validating novelty and inventiveness of the technology.
- Patent protection extends to 2045 if granted, covering Ebstrocel for epidermolysis bullosa and next-gen engineered modalities.
- Company plans to pursue additional patent applications in key global markets including the UK, Europe, Asia, and Latin America.
The big picture
INmune Bio’s advancement of its CORDStrom™ platform patent in the U.S. solidifies its intellectual property strategy amid a competitive biotech landscape focused on cell therapies. The move underscores the company's efforts to secure multi-decade market exclusivity for its lead program and next-generation modalities, aligning with broader industry trends toward proprietary platforms addressing manufacturing inconsistencies in MSC therapeutics.
What we're watching
- Patent Grant Likelihood
- Whether the USPTO will grant the patent given the favorable PCT opinion and its implications for long-term exclusivity.
- Global IP Strategy
- The pace at which INmune Bio secures corresponding patents in other high-value jurisdictions.
- Commercialization Timeline
- How the patent protection timeline aligns with the company's regulatory and commercialization plans for Ebstrocel.
Related topics